Overview

* Soligenix ( SNGX ) Q3 net loss widens to $2.5 mln due to increased clinical trial expenses

* Company reports no revenue for Q3 2025, same as Q3 2024

* Soligenix ( SNGX ) has $10.5 mln cash, providing runway through 2026

Outlook

* Soligenix anticipates top-line results from Phase 3 HyBryte™ study in H2 2026

* Company plans to carefully allocate resources to achieve strategic goals

* Soligenix ( SNGX ) exploring partnerships and financing to advance late-stage pipeline

Result Drivers

* CLINICAL TRIAL EXPENSES - Increased net loss attributed to higher costs from ongoing clinical trials, particularly the second confirmatory Phase 3 CTCL trial

* CASH MANAGEMENT - Co has $10.5 mln cash, focused on strategic resource allocation and exploring funding options

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$2.50

Income mln

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Soligenix Inc ( SNGX ) is $17.50, about 92.7% above its November 6 closing price of $1.28

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)